The promotion of 11Three Tech and the RELIEFTA™ patch isn't a new commercial breakthrough, this is just the pattern David has used for the past 8--10 years to keep investors interested / buying shares of UNVC.
The promotion surrounding 11Three Tech and its lead transdermal product (Reliefta) follows the exact structural blueprint as the 2018 Transdermal CBD Patch narrative---October 28, 2021 press release featuring bioRemedies MD, LLC and Patrick Kelly: then put in the in this case starting 2018 ending in 2020--Wellness RX merger promises $50,000 investment secured by promising a transaction/merger involving Wellness RX Corporation and Univec, Inc. ($UNVC), with representations that Wellness RX would serve as the surviving operational entity to be uplisted to a major exchange (NYSE). Case Docket: CV-2018-008314 (Court of Common Pleas of Delaware County, Pennsylvania.
No SEC/OTC filings show any partnership deals signed, no GAAP-recognized commercial revenue, binding institutional supply contracts, or operational income resulting from these touted partnerships.
No finished drug product listing or NDC code assigned to RELIEFTA™ or any other products in the FDA database. No Labeler /NDC code assigned to 11Three / Univec, CentennialRx.
All UNIVEC has is a CEO operating off speculation hype without producing binding contracts over the last 10 years. From the 2018 CBD Patch to bioRemedies MD and 11Three / RELIEFTA™, the strategy remains identical: cycling entity names and product labels to keep UNVC trading while delivering zero audited financial results.
Disclaimer--Not advise to sell or buy!!!
PL